NAS:CARA (USA) Also trade in: Germany

Cara Therapeutics Inc

$ 19.1 -0.3 (-1.55%)
Volume: 126,296 Avg Vol (1m): 662,575
Market Cap $: 754.96 Mil Enterprise Value $: 593.58 Mil
P/E (TTM): 0.00 P/B: 5.63
Earnings Power Value -104.66
Net Current Asset Value 2.81
Tangible Book 3.39
Projected FCF -3.79
Median P/S Value 30.6
Graham Number 0
Peter Lynch Value 0
DCF (FCF Based) 0
DCF (Earnings Based) 0
YTD (-%)

Financial Strength : 9/10

Current vs industry vs history
Cash-to-Debt No Debt
Equity-to-Asset 0.70
Interest Coverage No Debt
N/A
Piotroski F-Score 4
0
1
2
3
4
5
6
7
8
9
Altman Z-Score 5.33
DISTRESS
GREY
SAFE
Beneish M-Score 13.59
Not Manipulator
Manipulator
WACC vs ROIC %
ROIC 0%
WACC 20.17%

Profitability & Growth : 2/10

Current vs industry vs history
Operating Margin % -574.52
Net Margin % -549.51
ROE % -71.84
ROA % -51.32
ROC (Joel Greenblatt) % -7773.96
3-Year Total Revenue Growth Rate 52.40
3-Year Total EBITDA Growth Rate -46.80
N/A
3-Year EPS w/o NRI Growth Rate -27.20
N/A

» CARA's 30-Y Financials

Financials (Next Earnings Date: 2019-05-09)

Guru Trades Click for details

» Details

Insider Trades

SEC Filings

Gurus Latest Trades with NAS:CARA

» Interactive Chart

Peter Lynch Chart

Business Description

Industry Biotechnology » Biotechnology    NAICS : 325412    SIC : 2834
Compare SZSE:002868 WAR:CLN XPAR:IPH XSWX:SKIN NAS:IDRA NAS:ADVM XTER:MDG1 NAS:NITE NAS:SYRS LSE:ARIX NAS:PIRS SHSE:603229 NAS:MRSN TSXV:EMH LSE:CIR NAS:SNNA NAS:CORI OTCPK:RCAR OSTO:ONCO XKRX:019175
Traded in other countries 69C.Germany
Address 107 Elm Street, 9th Floor, 4 Stamford Plaza, Stamford, CT, USA, 06902
Cara Therapeutics is an emerging biotechnology company involved in the development of novel therapeutics to treat human diseases associated with inflammation, pain, and pruritus. Cara's most advanced compound, CR845, aims to treat acute pain and pruritus. This patented compound has analgesic, anti-inflammatory, and antipruritic properties that can be used for multiple therapeutic applications. Additionally, Cara's objective is to use its proprietary drug-screening technology to develop a future pipeline of first-in-class molecules with analgesic and anti-inflammatory features.

Ratios

Current vs industry vs history
PB Ratio 5.63
PS Ratio 53.17
EV-to-EBIT -7.69
EV-to-EBITDA -7.72
EV-to-Revenue 44.05
Current Ratio 4.16
Quick Ratio 4.16

Dividend & Buy Back

Current vs industry vs history
3-Year Share Buyback Rate -9.60

Valuation & Return

Current vs industry vs history
Price-to-Tangible-Book 5.63
Price-to-Median-PS-Value 0.62
Earnings Yield (Joel Greenblatt) % -13.04

More Statistics

Revenue (TTM) (Mil) $ 13.47
EPS (TTM) $ -2.06
Beta 2.93
Volatility % 60.52
52-Week Range $ 11.5 - 24.3
Shares Outstanding (Mil) 39.55

Analyst Estimate

Piotroski F-Score Details

Piotroski F-Score 4
Positive ROA N
Positive CFROA N
Higher ROA yoy Y
CFROA > ROA Y
Lower Leverage yoy Y
Higher Current Ratio yoy N
Less Shares Outstanding yoy N
Higher Gross Margin yoy N
Higher Asset Turnover yoy Y